USTRADER
продаде ли вече Авант? Ти сигурно си го купил на $1.90 - 1.93 през февруари, а сега е на 2.08 (+8%) и очакването е че ще пада още надолу.
Avant Immunotherapeutics Inc. (AVAN) accelerated a $40-million milestone
payment to the company that had been due upon the launch of its Rotarix
vaccine in the European Union.
The Needham, Mass., company amended its agreement with an affiliate of Paul
Royalty Fund II L.P. so that it will receive the payment March 17, rather than
on the first sale of Rotarix in the E.U., which is expected during the second
quarter.
Other financial terms of Avant's May 2005 agreement with Paul Royalty Fund
weren't changed. Avant received an upfront payment of $10 million and will get
$9 million to $11 million upon product launch in the U.S., depending on the
date of launch. The company will also get royalty revenue depending on
commercial success of the product.
продаде ли вече Авант? Ти сигурно си го купил на $1.90 - 1.93 през февруари, а сега е на 2.08 (+8%) и очакването е че ще пада още надолу.
Avant Immunotherapeutics Inc. (AVAN) accelerated a $40-million milestone
payment to the company that had been due upon the launch of its Rotarix
vaccine in the European Union.
The Needham, Mass., company amended its agreement with an affiliate of Paul
Royalty Fund II L.P. so that it will receive the payment March 17, rather than
on the first sale of Rotarix in the E.U., which is expected during the second
quarter.
Other financial terms of Avant's May 2005 agreement with Paul Royalty Fund
weren't changed. Avant received an upfront payment of $10 million and will get
$9 million to $11 million upon product launch in the U.S., depending on the
date of launch. The company will also get royalty revenue depending on
commercial success of the product.
Коментар